Enanta Pharmaceuticals Inc. (ENTA) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.15 (-3.46% 1D, market cap $324.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTA ranks #990 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRLD (Prelude Therapeutics Incorporated) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $327.2M) and TTRX (Turn Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -28.3%, cap $327.3M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.7% realized swing band)
FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 36.6 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ENTA currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.53) and Max Pain ($11.71) forces dealer call-delta covering toward $18.01.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Enanta Pharmaceuticals Inc. (ENTA) dropped -3.46% to $11.15, trading at 13% of its 52-week range ($10.22 – $17.15). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm
WATERTOWN, Mass., October 28, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces
WATERTOWN, Mass., October 26, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today ann
The Phase 2b/3 randomized, double-blind, placebo-controlled, multicenter global trial will evaluate the efficacy and safety of zelicapavir in adult outpatients who test positive for RSV and have had respiratory tract
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ENTA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ENTA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Enanta Pharmaceuticals Inc. (ENTA) ranks #990 by composite RQD confidence (25/100, grade E) and #513 by equity capitalization ($324.7M). Within this direct 5-issuer industry benchmark cohort, ENTA leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. PRLD currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ENTA at 25/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENTA
ACTIVE
Enanta Pharmaceuticals Inc. | E | 25/100 | — | — | -35.0% | -3.46% | $324.7M | Benchmark Subject |
| PRLD Prelude Therapeutics Incorporated | D- | 41/100 | — | — | -35.0% | -0.97% | $327.2M | /prld-vs-enta → |
| TTRX Turn Therapeutics Inc. | E | 31/100 | — | — | -28.3% | -3.60% | $327.3M | /ttrx-vs-enta → |
| BNTC Benitec Biopharma Inc. | D- | 37/100 | — | — | -35.0% | +0.34% | $308.1M | /bntc-vs-enta → |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 31/100 | — | — | -35.0% | +0.66% | $345.3M | /arct-vs-enta → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), Enanta Pharmaceuticals Inc. (ENTA) reported GAAP revenue of $65.3M (-3.4% vs. FY2024 revenue of $67.6M , and -17.5% cumulative change since FY2023) , GAAP net income of -$81.9M, operating cash flow of -$19.3M, and free cash flow of -$32.2M (+66.7% YoY). On the balance sheet, ENTA closed FY2025 with $329.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $65.3M | -$81.9M | -$19.3M | -$32.2M | $329.5M | — |
| FY2024 (FY) | 2024-09-30 | $67.6M | -$116.0M | -$78.8M | -$96.7M | $348.6M | — |
| FY2023 (FY) | 2023-09-30 | $79.2M | -$133.8M | -$103.2M | -$103.2M | — | — |
As of 2026-11-01, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.15 (-3.46% 1D, market cap $324.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTA ranks #990 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRLD (Prelude Therapeutics Incorporated) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $327.2M) and TTRX (Turn Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -28.3%, cap $327.3M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ENTA last traded at $11.15 (-3.46% on volume of 218,492 shares), positioning the stock -11.01% below its 50-day simple moving average ($12.53) and -15.47% below its 200-day simple moving average ($13.19). Across its 52-week range of $10.22 to $17.15, ENTA sits at the 13.4% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($9.85 to $12.45).
Why ENTA Stock dropped -3.46% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.